Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

The Oncology Nurse Advisor Summit spotlights CAR T-cell therapy, bispecific antibodies, and immunotherapy nursing best practices.

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...

Carol Meyers, 72, knew exactly how her daughter was feeling. Her daughter, Carley Yelyashov, 44, was in the hospital in June 2024 for a stem cell transplant, when healthy stem cells are infused into ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Stage 3 multiple myeloma is defined by high beta-2 microglobulin, elevated LDH, and high-risk genetic abnormalities. Diagnosis involves CRAB criteria and tests like bone marrow biopsy, imaging, and ...